Company
Alector
By harnessing insights from human genetics, neuroscience, and immunology, we’re advancing innovative therapies with the potential to counteract the devastating progression of neurodegenerative diseases.
Also known as Alector, Inc.
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- Legal name
- Alector, Inc.
- alector.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Alector, we combine scientific rigor and deep expertise in human genetics, immunology, neuroscience, protein and nucleic acid engineering, and artificial intelligence with our Alector Brain Carrier (ABC) technology to develop therapies designed to reach the brain and make a meaningful difference for people living with devastating neurodegenerative diseases.
Funding snapshot
- Total raised
- $32.3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $32.3M2015-09-01
Funding rounds
- Round, 2015
- $32.3M2015-09-01, SEC form D sold, 11 investors
Loading relationship preview